Zhengye Biotechnology Holding Ltd Ordinary Shares - Class A ZYBT

Morningstar Rating
$1.24 −0.02 (1.59%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ZYBT is trading at a LOCK|vJ$&V premium.
Price
$1.24
Fair Value
LOCK|GG$hC@
Uncertainty
LOCK|LV ^Vf?
1-Star Price
LOCK|&>#rp^!
5-Star Price
LOCK|xL^%&@
Economic Moat
LOCK|Y#!p
Capital Allocation
—

Trading Information

Previous Close Price
$1.26
Day Range
$1.20–1.26
52-Week Range
$0.62–8.01
Bid/Ask
$1.21 / $1.26
Shares Outstanding
47.39M
Market Cap
$58.77M
Volume/Avg
15,932 / 5M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
3.63
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
269

Valuation

Metric
ZYBT
Price/Earnings (Normalized)
—
Price/Book Value
1.65
Price/Sales
3.63
Price/Cash Flow
—
Price/Earnings
ZYBT

Financial Strength

Metric
ZYBT
Quick Ratio
0.58
Current Ratio
1.14
Interest Coverage
−20.17
Quick Ratio
ZYBT

Profitability

Metric
ZYBT
Return on Assets (Normalized)
−14.64%
Return on Equity (Normalized)
−25.21%
Return on Invested Capital (Normalized)
−15.73%
Return on Assets
ZYBT

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|@?f!>#?LOCK|mg@^@$67B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|pyfxb!C&LOCK|xj!K%$46B
Haleon PLC ADR
HLN
LOCK|rK<&#v&LOCK|$XQ$38B
Zoetis Inc Class A
ZTS
LOCK|$LBn^wvqLOCK|<Jx$29B
Viatris Inc
VTRS
LOCK|D#Whn&qLOCK|g^$20B
Elanco Animal Health Inc
ELAN
LOCK|ZZSLOCK|&$$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|#zY!?f$LOCK|pk#$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|&>D$?$>LOCK|>#$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|%v#!>@@LOCK|s&^?Y$2B
Perrigo Co PLC
PRGO
LOCK|Jym&?vHLOCK|>y$2B

Sponsor Center